{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:15:35Z","timestamp":1793196935200,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cushing\u2019s syndrome (CS) is associated with severe cardiovascular (CV) morbidity and mortality. Cardiac magnetic resonance (CMR) is the non-invasive gold standard for assessing cardiac structure and function; however, few CMR studies explore cardiac remodeling in patients exposed to chronic glucocorticoid (GC) excess. We aimed to describe the CMR features directly attributable to previous GC exposure in patients with cured or treated endogenous CS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective, multicentre, case-control study enrolling consecutive patients with cured or treated CS and patients harboring non-functioning adrenal incidentalomas (NFAI), comparable in terms of sex, age, CV risk factors, and BMI. All patients were in stable condition and had a minimum 24-month follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen patients with CS and 15 NFAI were enrolled. Indexed left ventricle (LV) end-systolic volume and LV mass were higher in patients with CS (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.027; p<\/jats:italic>\u2009=\u2009<jats:italic>0.013<\/jats:italic>); similarly, indexed right ventricle (RV) end-diastolic and end-systolic volumes were higher in patients with CS compared to NFAI (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.035; p<\/jats:italic>\u2009=\u2009<jats:italic>0.006<\/jats:italic>). Morphological alterations also affected cardiac function, as LV and RV ejection fractions decreased in patients with CS (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.056; p<\/jats:italic>\u2009=\u2009<jats:italic>0.044<\/jats:italic>). CMR features were independent of metabolic status or other CV risk factors, with fasting glucose significantly lower in CS remission than NFAI (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and no differences in lipid levels or blood pressure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CS is associated with biventricular cardiac structural and functional impairment at CMR, likely attributable to chronic exposure to cortisol excess independently of known traditional risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-024-03856-7","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:02:07Z","timestamp":1716382927000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac magnetic resonance reveals biventricular impairment in Cushing\u2019s syndrome: a multicentre case-control study"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-0064","authenticated-orcid":false,"given":"Tiziana","family":"Feola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-5873","authenticated-orcid":false,"given":"Alessia","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-1761","authenticated-orcid":false,"given":"Dario","family":"De Alcubierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5735","authenticated-orcid":false,"given":"Riccardo","family":"Pofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-5120","authenticated-orcid":false,"given":"Nicola","family":"Galea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-9691","authenticated-orcid":false,"given":"Carlo","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4275-337X","authenticated-orcid":false,"given":"Chiara","family":"Simeoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-874X","authenticated-orcid":false,"given":"Federica","family":"Campolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":false,"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-6151","authenticated-orcid":false,"given":"Elisa","family":"Giannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"3856_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The Treatment of Cushing\u2019s Disease. Endocr. Rev. 36, 385\u2013486 (2015). https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr. Rev."},{"key":"3856_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611\u2013629 (2016). https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3856_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing\u2019s syndrome. Lancet 367, 1605\u20131617 (2006). https:\/\/doi.org\/10.1016\/S0140-6736(06)68699-6","journal-title":"Lancet"},{"key":"3856_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ecl.2007.10.010","volume":"37","author":"R Pivonello","year":"2008","unstructured":"R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing\u2019s Syndrome. Endocrinol. Metab. Clin. North Am. 37, 135\u2013149 (2008). https:\/\/doi.org\/10.1016\/j.ecl.2007.10.010. ix","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"3856_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000314297","volume":"92","author":"C Steffensen","year":"2010","unstructured":"C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jorgensen, Epidemiology of Cushing\u2019s syndrome. Neuroendocrinology 92, 1\u20135 (2010). https:\/\/doi.org\/10.1159\/000314297","journal-title":"Neuroendocrinology"},{"key":"3856_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"R.N. Clayton, P.W. Jones, R.C. Reulen et al. Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol. 4, 569\u2013576 (2016). https:\/\/doi.org\/10.1016\/S2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3856_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"E. Valassi, A. Tabarin, T. Brue et al. High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur. J. Endocrinol. 181, 461\u2013472 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0464","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.tem.2020.04.004","volume":"31","author":"V Hasenmajer","year":"2020","unstructured":"V. Hasenmajer, E. Sbardella, F. Sciarra, M. Minnetti, A.M. Isidori, M.A. Venneri, The Immune System in Cushing\u2019s Syndrome. Trends Endocrinol. Metab. 31, 655\u2013669 (2020). https:\/\/doi.org\/10.1016\/j.tem.2020.04.004","journal-title":"Trends Endocrinol. Metab."},{"key":"3856_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1530\/EJE-22-0454","volume":"187","author":"M Minnetti","year":"2022","unstructured":"M. Minnetti, V. Hasenmajer, E. Sbardella et al. Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. Eur. J. Endocrinol. 187, 719\u2013731 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0454","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000318566","volume":"92","author":"M De Leo","year":"2010","unstructured":"M. De Leo, R. Pivonello, R.S. Auriemma et al. Cardiovascular disease in Cushing\u2019s syndrome: heart versus vasculature. Neuroendocrinology 92, 50\u201354 (2010). https:\/\/doi.org\/10.1159\/000318566","journal-title":"Neuroendocrinology"},{"key":"3856_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","volume":"33","author":"AM Isidori","year":"2015","unstructured":"A.M. Isidori, C. Graziadio, R.M. Paragliola et al. The hypertension of Cushing\u2019s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33, 44\u201360 (2015). https:\/\/doi.org\/10.1097\/HJH.0000000000000415","journal-title":"J. Hypertens."},{"key":"3856_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","volume":"61","author":"T Mancini","year":"2004","unstructured":"T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing\u2019s syndrome according to 1999 WHO\/ISH guidelines. Clin. Endocrinol. 61, 768\u2013777 (2004). https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02168.x","journal-title":"Clin. Endocrinol."},{"key":"3856_CR13","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-15-0308","volume":"173","author":"AM Isidori","year":"2015","unstructured":"A.M. Isidori, M. Minnetti, E. Sbardella, C. Graziadio, A.B. Grossman, Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur. J. Endocrinol. 173, R101\u2013R113 (2015). https:\/\/doi.org\/10.1530\/EJE-15-0308","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","volume":"40","author":"F Fallo","year":"2022","unstructured":"F. Fallo, G. Di Dalmazi, F. Beuschlein et al. Diagnosis and management of hypertension in patients with Cushing\u2019s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 40, 2085\u20132101 (2022). https:\/\/doi.org\/10.1097\/HJH.0000000000003252","journal-title":"J. Hypertens."},{"key":"3856_CR15","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"O.M. Dekkers, E. Horvath-Puho, J.O. Jorgensen et al. Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277\u20132284 (2013). https:\/\/doi.org\/10.1210\/jc.2012-3582","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3856_CR16","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling et al. Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015). https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3856_CR17","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/EJE-14-0556","volume":"172","author":"FM van Haalen","year":"2015","unstructured":"F.M. van Haalen, L.H. Broersen, J.O. Jorgensen, A.M. Pereira, O.M. Dekkers, Management of endocrine disease: Mortality remains increased in Cushing\u2019s disease despite biochemical remission: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R143\u2013R149 (2015). https:\/\/doi.org\/10.1530\/EJE-14-0556","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR18","doi-asserted-by":"publisher","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","volume":"99","author":"P Kamenicky","year":"2014","unstructured":"P. Kamenicky, A. Redheuil, C. Roux et al. Cardiac structure and function in Cushing\u2019s syndrome: a cardiac magnetic resonance imaging study. J. Clin. Endocrinol. Metab. 99, E2144\u2013E2153 (2014). https:\/\/doi.org\/10.1210\/jc.2014-1783","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3856_CR19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/s0735-1097(03)00493-5","volume":"41","author":"ML Muiesan","year":"2003","unstructured":"M.L. Muiesan, M. Lupia, M. Salvetti et al. Left ventricular structural and functional characteristics in Cushing\u2019s syndrome. J. Am. Coll. Cardiol. 41, 2275\u20132279 (2003). https:\/\/doi.org\/10.1016\/s0735-1097(03)00493-5","journal-title":"J. Am. Coll. Cardiol."},{"key":"3856_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0621","volume":"162","author":"AM Pereira","year":"2010","unstructured":"A.M. Pereira, V. Delgado, J.A. Romijn, J.W. Smit, J.J. Bax, R.A. Feelders, Cardiac dysfunction is reversed upon successful treatment of Cushing\u2019s syndrome. Eur. J. Endocrinol. 162, 331\u2013340 (2010). https:\/\/doi.org\/10.1530\/EJE-09-0621","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EJE-11-0601","volume":"166","author":"KH Yiu","year":"2012","unstructured":"K.H. Yiu, N.A. Marsan, V. Delgado et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing\u2019s syndrome. Eur. J. Endocrinol. 166, 27\u201334 (2012). https:\/\/doi.org\/10.1530\/EJE-11-0601","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR22","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/jcem.84.8.5896","volume":"84","author":"A Colao","year":"1999","unstructured":"A. Colao, R. Pivonello, S. Spiezia et al. Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664\u20132672 (1999). https:\/\/doi.org\/10.1210\/jcem.84.8.5896","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3856_CR23","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"A. Faggiano, R. Pivonello, S. Spiezia et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol. Metab. 88, 2527\u20132533 (2003). https:\/\/doi.org\/10.1210\/jc.2002-021558","journal-title":"J Clin Endocrinol. Metab."},{"key":"3856_CR24","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.3390\/jcm11237035","volume":"11","author":"A Kanzaki","year":"2022","unstructured":"A. Kanzaki, M. Kadoya, S. Katayama, H. Koyama, Cardiac Hypertrophy and Related Dysfunctions in Cushing Syndrome Patients-Literature Review. J. Clin. Med. 11, 7035 (2022). https:\/\/doi.org\/10.3390\/jcm11237035","journal-title":"J. Clin. Med."},{"key":"3856_CR25","doi-asserted-by":"publisher","first-page":"e003951","DOI":"10.1161\/CIRCIMAGING.116.003951","volume":"10","author":"M Salerno","year":"2017","unstructured":"M. Salerno, B. Sharif, H. Arheden et al. Recent Advances in Cardiovascular Magnetic Resonance: Techniques and Applications. Circ. Cardiovasc. Imaging 10, e003951 (2017). https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.003951","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"3856_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jmri.25374","volume":"45","author":"C Roux","year":"2017","unstructured":"C. Roux, N. Kachenoura, Z. Raissuni et al. Effects of cortisol on the heart: characterization of myocardial involvement in cushing\u2019s disease by longitudinal cardiac MRI T1 mapping. J. Magn. Reson. Imaging 45, 147\u2013156 (2017). https:\/\/doi.org\/10.1002\/jmri.25374","journal-title":"J. Magn. Reson. Imaging"},{"key":"3856_CR27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.jacc.2018.07.096","volume":"72","author":"F Maurice","year":"2018","unstructured":"F. Maurice, B. Gaborit, C. Vincentelli et al. Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. J. Am. Coll. Cardiol. 72, 2276\u20132277 (2018). https:\/\/doi.org\/10.1016\/j.jacc.2018.07.096","journal-title":"J. Am. Coll. Cardiol."},{"key":"3856_CR28","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1210\/clinem\/dgab556","volume":"106","author":"P Wolf","year":"2021","unstructured":"P. Wolf, B. Marty, K. Bouazizi et al. Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. J. Clin. Endocrinol. Metab. 106, 3505\u20133514 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab556","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3856_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12020-023-03623-0","volume":"83","author":"M Moustaki","year":"2024","unstructured":"M. Moustaki, G. Markousis-Mavrogenis, A. Vryonidou, S.A. Paschou, S. Mavrogeni, Cardiac disease in Cushing\u2019s syndrome. Emphasis on the role of cardiovascular magnetic resonance imaging. Endocrine 83, 548\u2013558 (2024). https:\/\/doi.org\/10.1007\/s12020-023-03623-0","journal-title":"Endocrine"},{"key":"3856_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"M. Fleseriu, R. Auchus, I. Bancos et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847\u2013875 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3856_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101485","volume":"35","author":"JM Hinojosa-Amaya","year":"2021","unstructured":"J.M. Hinojosa-Amaya, D. Cuevas-Ramos, The definition of remission and recurrence of Cushing\u2019s disease. Best. Pract. Res. Clin. Endocrinol. Metab. 35, 101485 (2021). https:\/\/doi.org\/10.1016\/j.beem.2021.101485","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"3856_CR32","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"M. Fassnacht, S. Tsagarakis, M. Terzolo et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 189, G1\u2013G42 (2023). https:\/\/doi.org\/10.1093\/ejendo\/lvad066","journal-title":"Eur. J. Endocrinol."},{"key":"3856_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcmg.2020.10.009","volume":"14","author":"R Pofi","year":"2021","unstructured":"R. Pofi, E. Giannetta, N. Galea et al. Diabetic Cardiomiopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study. JACC Cardiovasc. Imaging. 14, 1130\u20131142 (2021). https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.009","journal-title":"JACC Cardiovasc. Imaging."},{"key":"3856_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"J.C. Moon, D.R. Messroghli, P. Kellman et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J. Cardiovasc. Magn. Reson. 15, 92 (2013). https:\/\/doi.org\/10.1186\/1532-429X-15-92","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"3856_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","volume":"18","author":"P Haaf","year":"2016","unstructured":"P. Haaf, P. Garg, D.R. Messroghli, D.A. Broadbent, J.P. Greenwood, S. Plein, Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J. Cardiovasc. Magn. Reson. 18, 89 (2016). https:\/\/doi.org\/10.1186\/s12968-016-0308-4","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"3856_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","volume":"22","author":"N Kawel-Boehm","year":"2020","unstructured":"N. Kawel-Boehm, S.J. Hetzel, B. Ambale-Venkatesh et al. Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J. Cardiovasc. Magn. Reson. 22, 87 (2020). https:\/\/doi.org\/10.1186\/s12968-020-00683-3","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"3856_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1586\/erc.10.190","volume":"9","author":"R Janardhanan","year":"2011","unstructured":"R. Janardhanan, C.M. Kramer, Imaging in hypertensive heart disease. Expert Rev. Cardiovasc. Ther. 9, 199\u2013209 (2011). https:\/\/doi.org\/10.1586\/erc.10.190","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"3856_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1540-8175.2007.00572.x","volume":"25","author":"M Baykan","year":"2008","unstructured":"M. Baykan, C. Erem, O. Gedikli et al. Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing\u2019s Syndrome. Echocardiography 25, 182\u2013190 (2008). https:\/\/doi.org\/10.1111\/j.1540-8175.2007.00572.x","journal-title":"Echocardiography"},{"key":"3856_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF03346461","volume":"32","author":"NA Bayram","year":"2009","unstructured":"N.A. Bayram, R. Ersoy, C. Aydin et al. Assessment of left ventricular functions by tissue Doppler echocardiography in patients with Cushing\u2019s disease. J. Endocrinol. Invest. 32, 248\u2013252 (2009). https:\/\/doi.org\/10.1007\/BF03346461","journal-title":"J. Endocrinol. Invest."},{"key":"3856_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","volume":"76","author":"PM Toja","year":"2012","unstructured":"P.M. Toja, G. Branzi, F. Ciambellotti et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing\u2019s syndrome before and after cure. Clin. Endocrinol. 76, 332\u2013338 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04206.x","journal-title":"Clin. Endocrinol."},{"key":"3856_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2019.103940","volume":"128","author":"F Tona","year":"2020","unstructured":"F. Tona, M. Boscaro, M. Barbot et al. New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing\u2019s syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Microvasc. Res. 128, 103940 (2020). https:\/\/doi.org\/10.1016\/j.mvr.2019.103940","journal-title":"Microvasc. Res."},{"key":"3856_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jcmg.2012.06.003","volume":"5","author":"AC Armstrong","year":"2012","unstructured":"A.C. Armstrong, S. Gidding, O. Gjesdal, C. Wu, D.A. Bluemke, J.A. Lima, LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc. Imaging 5, 837\u2013848 (2012). https:\/\/doi.org\/10.1016\/j.jcmg.2012.06.003","journal-title":"JACC Cardiovasc. Imaging"},{"key":"3856_CR43","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/s0024-3205(96)00539-5","volume":"59","author":"C Sylven","year":"1996","unstructured":"C. Sylven, E. Jansson, P. Sotonyi, F. Waagstein, T. Barkhem, M. Bronnegard, Cardiac nuclear hormone receptor mRNA in heart failure in man. Life Sci. 59, 1917\u20131922 (1996). https:\/\/doi.org\/10.1016\/s0024-3205(96)00539-5","journal-title":"Life Sci."},{"key":"3856_CR44","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","volume":"54","author":"AS Mihailidou","year":"2009","unstructured":"A.S. Mihailidou, T.Y. Loan Le, M. Mardini, J.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54, 1306\u20131312 (2009). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.136242","journal-title":"Hypertension"},{"key":"3856_CR45","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/endo.142.8.8339","volume":"142","author":"G Fujisawa","year":"2001","unstructured":"G. Fujisawa, R. Dilley, M.J. Fullerton, J.W. Funder, Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142, 3625\u20133631 (2001). https:\/\/doi.org\/10.1210\/endo.142.8.8339","journal-title":"Endocrinology"},{"key":"3856_CR46","doi-asserted-by":"publisher","first-page":"R343","DOI":"10.1152\/ajpregu.00112.2013","volume":"305","author":"X Feng","year":"2013","unstructured":"X. Feng, S.A. Reini, E. Richards, C.E. Wood, M. Keller-Wood, Cortisol stimulates proliferation and apoptosis in the late gestation fetal heart: differential effects of mineralocorticoid and glucocorticoid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R343\u2013R350 (2013). https:\/\/doi.org\/10.1152\/ajpregu.00112.2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"3856_CR47","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004872-199610003-00007","volume":"14","author":"PM Williamson","year":"1996","unstructured":"P.M. Williamson, J.J. Kelly, J.A. Whitworth, Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J. Hypertens. Suppl. 14, S37\u2013S41 (1996)","journal-title":"J. Hypertens. Suppl."},{"key":"3856_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ecl.2011.01.010","volume":"40","author":"SL Ong","year":"2011","unstructured":"S.L. Ong, J.A. Whitworth, How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol. Metab. Clin. North. Am. 40, 393\u2013407 (2011). https:\/\/doi.org\/10.1016\/j.ecl.2011.01.010","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"3856_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10741-019-09824-y","volume":"25","author":"A De Bellis","year":"2020","unstructured":"A. De Bellis, G. De Angelis, E. Fabris, A. Cannata, M. Merlo, G. Sinagra, Gender-related differences in heart failure: beyond the \u201cone-size-fits-all\u201d paradigm. Heart Fail. Rev. 25, 245\u2013255 (2020). https:\/\/doi.org\/10.1007\/s10741-019-09824-y","journal-title":"Heart Fail. Rev."},{"key":"3856_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl8503","volume":"14","author":"R Pofi","year":"2022","unstructured":"R. Pofi, E. Giannetta, T. Feola et al. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci. Transl. Med. 14, eabl8503 (2022). https:\/\/doi.org\/10.1126\/scitranslmed.abl8503","journal-title":"Sci. Transl. Med."},{"key":"3856_CR51","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2174\/0929867324666161118121647","volume":"24","author":"D Gianfrilli","year":"2017","unstructured":"D. Gianfrilli, R. Pofi, T. Feola, A. Lenzi, E. Giannetta, The Woman\u2019s Heart: Insights into New Potential Targeted Therapy. Curr. Med. Chem. 24, 2650\u20132660 (2017). https:\/\/doi.org\/10.2174\/0929867324666161118121647","journal-title":"Curr. Med. Chem."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03856-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:01:54Z","timestamp":1722427314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03856-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3856"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03856-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RPi has received research support to Universit\u00e0 Federico II di Napoli as a principal investigator for clinical trials from Novartis Pharma, Recordati, Strongbridge Biopharma, Corcept Therapeutics, HRA Pharma, Shire, Takeda, Neurocrine Biosciences, Camurus AB, and Pfizer, has received research support to Universit\u00e0 Federico II di Napoli from Pfizer, Ipsen, Novartis Pharma, Strongbridge Biopharma, Merk Serono, and Ibsa, and received occasional consulting honoraria from Novartis Pharma, Recordati, Strongbridge Biopharma, HRA Pharma, Crinetics Pharmaceuticals, Corcept Therapeutics, Pfizer, and Bresmed Health Solutions. AMI has been a consultant for Novartis, Takeda, Recordati, and Sandoz companies and has received unconditional research grants from Shire, IPSEN, and Pfizer. All the other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig. .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All patients provided written informed consent after fully explaining the purpose and nature of all procedures used. The study was approved by the Ethical Committee of Policlinico Umberto I (ref. number 4245). The study has been performed according to the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and conset to participate"}}]}}